Tepmetko

(Tepotinib)

Tepmetko

Drug updated on 11/15/2023

Dosage FormTablet (oral; 225 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.